FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
Are biological drugs safe in pregnancy?
4322Downloads: 2744 -
PO:16:231 | Differential clinical features of systemic lupus erythematosus patients on biological therapies: insights from a monocentric cohort Pietro Francesco Pilo, Elisa Bellis, Claudia Garulli, Claudio Cruciani, Marta Saracco, Claudia Lomater, Elena Marucco, Gloria Crepaldi, Valeria Data, Annamaria Iagnocco, Mariele Gatto. | Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Torino, Italy.
248 -
Knuckle pads mimic early psoriatic arthritis
16691Downloads: 1094 -
PO:01:015 | Assessment of the impact of the co-occurrence of psoriasis on the clinical and therapeutic pattern of a single-centre cohort of patients with spondyloarthritis associated with chronic inflammatory bowel disease Andrea Pace1, Marcella Falconi1, Alberto Floris1|2, Leonardo Sichi1, Francesca Onnis3, Lorenzo Meli3, Raffaela Piras3, Nicola Lutzu3, Federica Olla3, Agnese Favale3, Sara Onali3, Massimo Claudio Fantini3, Matteo Piga1|2, Alberto Cauli1|2. | 1SC Reumatologia, Dipartimento di Scienze Mediche e Salute Pubblica, Università di Cagliari, Cagliari, Italy; 2SC Reumatologia, AOU Cagliari, Cagliari, Italy; 3SC Gastroenterologia, AOU Cagliari, Cagliari, Italy.
250 -
PO:01:003 | Sex-based differences in 2 years treatment outcomes with b/ts-DMARDs in psoriatic arthritis: from real-world evidence to predictive modeling from the Gruppo Italiano Studio Early Arthritis (GISEA) prospective registry Simone Perniola1, Florenzo Iannone1, Francesco Paolo Cantatore2, Angelo Semeraro3, Leonardo Santo4, Roberto Gorla5, Alberto Cauli6, Roberto Felice Caporali7, Bruno Frediani8, Rosario Foti9, Fabrizio Conti10, Marco Sebastiani11, Maria Sole Chimenti12, Roberta Ramonda13, Fabiola Atzeni14, Maurizio Rossini15, Serena Bugatti16, Serena Guiducci17, Giovanni Lapadula1, Gianfranco Ferraccioli18, Francesca Romana Spinelli10, Elisa Gremese19. | 1Rheumatology Unit, DiMePReJ, University of Bari, Bari; 2Rheumatology Unit, Department of Medical and Surgical Sciences, Azienda Ospedaliero-Universitaria Policlinico Riuniti, Foggia; 3Rheumatology Unit, Martina Franca Hospital; 4Rheumatology Unit, ASL BT, P.O. Barletta; 5Rheumatology and Clinical Immunology Unit, ASST Spedali Civili of Brescia; 6Rheumatology Unit, Department of Medical Science and Public Health, University of Cagliari, Monserrato (CA); 7Rheumatology Unit, Dipartimento di Reumatologia e Scienze Mediche, ASST PINI-CTO, University of Milano, Milano; 8Rheumatology Unit, Azienda Ospedaliero Universitaria Senese, Siena; 9Rheumatology Unit, A.O.U. Policlinico S. Marco, Catania; 10Rheumatology Unit, Department of Clinical Internal, Anesthesiologic and CV Sciences, Sapienza University of Rome, Roma; 11Rheumatology Unit, AUSL Piacenza, University of Parma, Parma; 12Rheumatology, Department of Systems Medicine, University of Rome Tor Vergata, Roma; 13Rheumatology Unit, DIMED, University of Padua, Padova; 14Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina, Messina; 15Rheumatology Unit, Department of Medicine, University of Verona, Verona; 16Division of Rheumatology, Dept. of Internal Medicine and Therapy, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia; 17Division of Rheumatology, Department of Experimental and Clinical Medicine, University of Firenze, Firenze; 18Department of Medicine, Catholic University of the Sacred Heart, Fondazione Policlinico Gemelli IRCCS, Roma; 19Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Humanitas University, Rozzano (MI), Italy
291 -
MicroRNAs in autoimmune rheumatic diseases
1118Downloads: 1045 -
PO:36:252 | Long-Term Outcomes of Patients with Takayasu Arteritis in the Era of Biological Agents: a Multicenter International Study Alessandro Tomelleri1, Durga Prasanna Misra2, Fatma Alibaz-Oner3, Chiara Marvisi4, Chiara Calabrese1, Upendra Rathore2, Aysegul Avcu3, Adele Del Giudice4, Elisabetta Olivi4, Caterina Ricordi4, Corrado Campochiaro1, Elena Baldissera1, Marco Matucci-Cerinic1, Haner Direskeneli3, Carlo Salvarani4, Lorenzo Dagna1 | 1IRCCS Ospedale San Raffaele, Unità di Immunologia, Reumatologia, Allergologia e Malattie Rare Milano, Italy; 2Sanjay Gandhi Postgraduate Institute of Medical Sciences SGPGIMS, Clinical Immunology and Rheumatology Lucknow Country, India; 3Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology Istanbul, Turkey; 4Azienda USL-IRCCS di Reggio Emilia, Unità di Reumatologia Reggio Emilia, Italy
123 -
PO:15:209 | Attainment of remission or lupus low disease activity state in single center Lupus Clinic Paola Tedoldi1|2, Silvia Ebe Lucia Della Pina1|2, Claudia Barison1|2, Chiara Orlandi1|2, Cecilia Nalli1, Micaela Fredi2, Ilaria Cavazzana1|2, Franco Franceschini1|2 | 1Rheumatology and Clinical Immunology Unit- ERN ReCONNET, ASST Spedali Civili of Brescia Brescia, Italy; 2Department of Clinical and Experimental Sciences, University of Brescia Brescia, Italy
128 -
PO:02:017 | Difficult-to-treat psoriatic arthritis: clinical and ultrasonographic predictors in a real-life cohort Federico Favaro1, Elisa Bellis1, Claudio Cruciani1, Gloria Crepaldi1, Valeria Data1, Claudia Garulli1, Claudia Lomater1, Elena Marucco1, Marta Saracco1, Mariele Gatto1, Annamaria Iagnocco1. | 1Academic Rheumatology Centre, Departement of Clinical and Biological Sciences, University of Turin, AO Mauriziano, Torino, Italy.
222 -
PO:01:004 | Real-world retention of IL-17 inhibitors in psoriatic arthritis: impact of prior IL-17 exposure across multiple treatment lines in the “BIRRA” multicentre cohort Valentino Paci1, Alarico Ariani2, Eleonora Celletti3, Alberto Lo Gullo4, Camilla Mazzanti5, Valeria Nucera6, Natalia Mansueto7, Rosalba Caccavale8, Patrizia Del Medico9, Antonella Farina10, Palma Scolieri11, Cecilia Giampietro12, Olga Addimanda13, Riccardo Bixio14, Maddalena Larosa15, Viviana Ravagnani16, Federica Lumetti17, Aldo Biagio Molica Colella17, Elena Bravi17, Rosetta Vitetta17, Bernd Raffeiner17, Gilda Sandri18, Rosario Foti19, Simone Parisi20, Michele Maria Luchetti Gentiloni1, Gianluca Moroncini1. | 1Clinical Medicine, Department of Clinical and Molecular Sciences, Marche Polytechnic University, AOU delle Marche, Ancona, Italy; 2Internal Medicine and Rheumatology Unit, University Hospital of Parma, Parma, Italy; 3Rheumatology Unit, Clinica Medica Institute, Ospedale SS. Annunziata di Chieti, G.d'Annunzio University of Chieti, Chieti, Italy; 4Rheumatology Unit, ARNAS Garibaldi di Catania, Catania, Italy; 5Center for the Diagnosis and Therapy of Autoimmune Rheumagological Diseases, Ospedale Santa Rosa, ASL Viterbo Viterbo Italy; 6Rheumatology Outpatient Unit, ASL Novara, Novara, Italy; 7Ambulatori di Reumatologia ASL1 Liguria, Imperia Hospitall Imperia Italy; 8Department of Clinical, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Polo Pontino, Roma, Italy; 9Rheumatology outpatient clinic - Internal Medicine Unit, Civitanova Marche Hospital, Civitanova Marche, Italy; 10Internal Medicine Unit, Rheumatology outpatient clinic, Ospedale A. Murri di Fermo, Fermo, Italy; 11Department of Medical Specialties, Nuovo Regina Margherita Hospital, Rome, Roma, Italy; 12Rheumatology Outpatient Clinic, Azienda ULSS 6 Euganea, Padova, Padova, Italy; 13Rheumatology Unit, Azienda Unità Sanitaria Locale di Bologna -- Policlinico S.Orsola- AOU di Bologna, Bologna, Italy; 14Rheumatology Unit, IRCCS Sacro Cuore Don Calabria Hospital, Negrar di Valpolicella, Verona, Italy; 15Division of Rheumatology - Medical Specialties Department, Ospedale La Colletta-Azienda Sanitaria Locale 3, Genova, Italy; 16Rheumatology Unit, Santa Chiara Hospital APSS Trento Italy; 17BIRRA - BIologic Retention Rate in chronic Arthritis - study group, Parma, Italy; 18Rheumatology Unit, University of Modena and Reggio Emilia, Modena, Italy; 19Rheumatology Unit, Policlinico San Marco Hospital, Catania, Italy; 20Rheumatology Department, Azienda Ospedaliera Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
344 -
PO:15:224 | Measuring disease activity in Systemic Lupus Erythematosus patients: SLE-DAS usefulness in real-life setting Valeria Moretti, Fulvia Ceccarelli, Claudia Ciancarella, Cristina Garufi, Alessandra Ida Celia, Silvia Mancuso, Angelica Gattamelata, Simona Truglia, Francesca Romana Spinelli, Cristiano Alessandri, Fabrizio Conti | La sapienza Università di Roma, Italy
70 -
Plasma procalcitonin in rheumatic diseases
1740Downloads: 5438 -
PO:14:195 | Real-world effectiveness of anifrolumab in achieving treatment targets and reducing systemic lupus erythematosus disease burden: 6-month interim analysis of the REVEAL study Chiara Cardelli1|2, Chiara Tani1, Luca Moroni3, Filippo Vesentini4, Francesca Bottazzi5, Micaela Fredi6, Ettore Silvagni7, Matteo Piga8, Flavia Riccio9, Fulvia Ceccarelli10, Ginevra De Marchi11, Edoardo Biancalana12, Gianluca Moroncini13, Rita Mulè14, Mariele Gatto15, Laura Coladonato16, Paola Conigliaro17, Maria Gerosa18, Andrea Picchianti Diamanti19, Benedetta Bianchi20, Federica Maiolini20, Michela Gasparotto20, Serena Guiducci20, Maria Ilenia De Andres20, Alberto Lo Gullo20, Silvia Noviello20, On Behalf Of The Reveal Investigators20, Marta Mosca1. | 1Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa; 2Department of Medical Biotechnologies, University of Siena, Siena; 3Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Milano; 4Rheumatology Unit, Department of Medicine, University of Padua, Padova; 5Department of Internal Medicine and Therapeutics, University of Pavia, Pavia; 6Rheumatology and Clinical Immunology, Department of Clinical and Experimental Sciences, University of Brescia, Brescia; 7Section of Rheumatology, Department of Medical Sciences, University of Ferrara; AOU Sant'Anna, Ferrara; 8Rheumatology Unit, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari; 9Department of Precision Medicine, University of Campania Luigi Vanvitelli, Napoli; 10Rheumatology Unit, Dept. of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Rome, Roma; 11Division of Rheumatology, Department of Medicine, Azienda Sanitaria Universitaria del Friuli Centrale, Udine; 12Internal Interdisciplinary Medicine Unit, Department of Experimental and Clinical Medicine, University of Florence, Firenze; 13Department of Clinical and Molecular Sciences, Marche Polytechnic University, Ancona; 14Azienda Ospedaliero-Universitaria di Bologna, Internal Medicine and Rheumatology, IRCCS S. Orsola Malpighi, Bologna; 15Academic Rheumatology Centre, Department of Clinical and Biological Sciences, University of Turin; AO Mauriziano, Torino; 16Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari, Bari; 17Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University of Rome, Roma; 18Clinical Rheumatology, ASST Gaetano Pini CTO; Department of Clinical Sciences and Community Health, University of Milano, Milano; 19Department of Clinical and Molecular Medicine, Sapienza University of Rome; AOU Sant'Andrea, Roma, Italy; 20Italian REVEAL Study Group Italy, Italy
310 -
PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara1, Gilberto Cincinelli1|2, Marco Fornaro3, Simone Perniola4, Elisa Gremese5, Chiara Bazzani6, Serena Bugatti7, Francesca Romana Spinelli8, Rosario Foti9, Marco Sebastiani10, Alberto Cauli11, Fabiola Atzeni12, Giovanni Lapadula13, Gianfranco Ferraccioli14, Fabrizio Conti8, Florenzo Iannone3, Roberto Caporali1|2 | 1Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; 2Department of Clinical Sciences and Community Health, University of Milan; 3Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; 4Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; 5Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); 6Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; 7Department of Internal Medicine and Therapeutics, Università di Pavia; 8Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; 9Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; 10Rheumatology Unit, AUSL Piacenza, University of Parma; 11UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; 12Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; 13Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; 14Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy
305 -
Safety of anti-TNFa biological drugs
1443Downloads: 1594 -
CO:10:3 | Clinical response to JAK inhibitors or non-TNFi-targeted biologicals according to synovial tissue characteristics in patients with difficult-to-treat rheumatoid arthritis Mariangela Salvato1, Alessandro Giollo1, Francesca Frizzera1, Kiren Khalid1, Lorenzo Di Luozzo1, Maria Capita1, Marianna Tamussin1, Carlo Garaffoni2, Marny Fedrigo3, Annalisa Angelini3, Ettore Silvagni2, Andrea Doria1. | 1Rheumatology Unit, Department of Medicine - DIMED, University of Padova; 2Rheumatology Unit, Department of Medical Sciences, University of Ferrara and Azienda Ospedaliero-Universitaria S. Anna; 3Cardiovascular Pathology, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Italy
294
